- Home
- PVL vs ALGS Comparison
PVL vs ALGS Comparison
Compare PVL & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVL
- ALGS
- Stock Information
- Founded
- PVL 2011
- ALGS 2018
- Country
- PVL United States
- ALGS United States
- Employees
- PVL N/A
- ALGS N/A
- Industry
- PVL Oil & Gas Production
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- PVL Energy
- ALGS Health Care
- Exchange
- PVL Nasdaq
- ALGS Nasdaq
- Market Cap
- PVL 57.8M
- ALGS 64.8M
- IPO Year
- PVL N/A
- ALGS 2020
- Fundamental
- Price
- PVL $1.79
- ALGS $6.92
- Analyst Decision
- PVL
- ALGS Strong Buy
- Analyst Count
- PVL 0
- ALGS 2
- Target Price
- PVL N/A
- ALGS $60.00
- AVG Volume (30 Days)
- PVL 66.2K
- ALGS 98.5K
- Earning Date
- PVL 01-01-0001
- ALGS 11-06-2025
- Dividend Yield
- PVL 19.89%
- ALGS N/A
- EPS Growth
- PVL N/A
- ALGS N/A
- EPS
- PVL 0.09
- ALGS N/A
- Revenue
- PVL $4,598,992.00
- ALGS $3,174,000.00
- Revenue This Year
- PVL N/A
- ALGS N/A
- Revenue Next Year
- PVL N/A
- ALGS N/A
- P/E Ratio
- PVL $19.35
- ALGS N/A
- Revenue Growth
- PVL 37.78
- ALGS N/A
- 52 Week Low
- PVL $1.30
- ALGS $3.76
- 52 Week High
- PVL $2.04
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- PVL 45.47
- ALGS 27.43
- Support Level
- PVL $1.79
- ALGS $9.25
- Resistance Level
- PVL $1.88
- ALGS $8.76
- Average True Range (ATR)
- PVL 0.06
- ALGS 0.75
- MACD
- PVL 0.00
- ALGS -0.30
- Stochastic Oscillator
- PVL 33.40
- ALGS 16.50
About PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.